Heterogeneity of KRAS Mutation Status in Rectal Cancer.

Anti-EGFR targeted therapy is of increasing importance in advanced colorectal cancer and prior KRAS mutation testing is mandatory for therapy. However, at which occasions this should be performed is still under debate. We aimed to assess in patients with locally advanced rectal cancer whether there...

Cijeli opis

Bibliografski detalji

Glavni autori:	Peter Jo, Alexander König, Markus Schirmer, Julia Kitz, Lena-Christin Conradi, Azadeh Azizian, Markus Bernhardt, Hendrik A Wolff, Marian Grade, Michael Ghadimi, Philipp Ströbel, Hans-Ulrich Schildhaus, Jochen Gaedcke
Format:	Artigo
Jezik:	Inglês
Izdano:	Public Library of Science (PLoS) 2016-01-01
Serija:	PLoS ONE
Online pristup:	http://europepmc.org/articles/PMC4827807?pdf=render
Oznake:	Dodaj oznaku Bez oznaka, Budi prvi tko označuje ovaj zapis!